Home
About
Overview
Sharing Data
ORCID
Help
History (8)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Unconventional myosin traffic in cells reveals a selective actin cytoskeleton.
Mitochondrial Uncoupling Proteins
Palmatine from Mahonia bealei attenuates gut tumorigenesis in ApcMin/+ mice via inhibition of inflammatory cytokines.
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
See All 8 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
View in:
PubMed
subject areas
Aged
Aged, 80 and over
Apoptosis
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Cell Movement
Cell Proliferation
Drug Resistance, Neoplasm
Female
Gene Amplification
Hepatocyte Growth Factor
Humans
Lung Neoplasms
Male
Mutation
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Signal Transduction
authors with profiles
Ravi Salgia